248 related articles for article (PubMed ID: 20370670)
1. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease.
Tönjes A; Blüher M; Stumvoll M
Curr Pharm Des; 2010 Jun; 16(17):1921-8. PubMed ID: 20370670
[TBL] [Abstract][Full Text] [Related]
2. [The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease].
Orlik B; Handzlik G; Olszanecka-Glinianowicz M
Postepy Hig Med Dosw (Online); 2010 May; 64():212-9. PubMed ID: 20498498
[TBL] [Abstract][Full Text] [Related]
3. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort.
Kashyap SR; Diab DL; Baker AR; Yerian L; Bajaj H; Gray-McGuire C; Schauer PR; Gupta M; Feldstein AE; Hazen SL; Stein CM
Obesity (Silver Spring); 2009 Sep; 17(9):1696-701. PubMed ID: 19360015
[TBL] [Abstract][Full Text] [Related]
4. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Wu H; Jia W; Bao Y; Lu J; Zhu J; Wang R; Chen Y; Xiang K
Diabetes Res Clin Pract; 2008 Feb; 79(2):185-90. PubMed ID: 17904683
[TBL] [Abstract][Full Text] [Related]
5. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease.
Martínez-Clemente M; Clària J; Titos E
Curr Opin Clin Nutr Metab Care; 2011 Jul; 14(4):347-53. PubMed ID: 21587068
[TBL] [Abstract][Full Text] [Related]
6. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis.
Tilg H
Curr Pharm Des; 2010 Jun; 16(17):1893-5. PubMed ID: 20370678
[TBL] [Abstract][Full Text] [Related]
7. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease.
Boyraz M; Cekmez F; Karaoglu A; Cinaz P; Durak M; Bideci A
Biomark Med; 2013 Oct; 7(5):737-45. PubMed ID: 24044566
[TBL] [Abstract][Full Text] [Related]
8. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease.
Ayonrinde OT; Olynyk JK; Beilin LJ; Mori TA; Pennell CE; de Klerk N; Oddy WH; Shipman P; Adams LA
Hepatology; 2011 Mar; 53(3):800-9. PubMed ID: 21374659
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
Polyzos SA; Kountouras J; Zavos C
Curr Mol Med; 2009 Apr; 9(3):299-314. PubMed ID: 19355912
[TBL] [Abstract][Full Text] [Related]
10. Retinol binding protein-4 circulating levels were higher in nonalcoholic fatty liver disease vs. histologically normal liver from morbidly obese women.
Terra X; Auguet T; Broch M; Sabench F; Hernández M; Pastor RM; Quesada IM; Luna A; Aguilar C; del Castillo D; Richart C
Obesity (Silver Spring); 2013 Jan; 21(1):170-7. PubMed ID: 23505183
[TBL] [Abstract][Full Text] [Related]
11. The association between retinol-binding protein 4 and prediabetes in obese patients with nonalcoholic fatty liver disease.
Karamfilova V; Gateva A; Alexiev A; Zheleva N; Velikova T; Ivanova-Boyanova R; Ivanova R; Cherkezov N; Kamenov Z; Mateva L
Arch Physiol Biochem; 2022 Feb; 128(1):217-222. PubMed ID: 31588816
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin: a key player in obesity related disorders.
Matsuzawa Y
Curr Pharm Des; 2010 Jun; 16(17):1896-901. PubMed ID: 20370675
[TBL] [Abstract][Full Text] [Related]
13. Serum retinol-binding protein 4 is independently associated with pediatric NAFLD and fasting triglyceride level.
Huang SC; Yang YJ
J Pediatr Gastroenterol Nutr; 2013 Feb; 56(2):145-50. PubMed ID: 22983378
[TBL] [Abstract][Full Text] [Related]
14. Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice.
Tan Y; Sun LQ; Kamal MA; Wang X; Seale JP; Qu X
Biochim Biophys Acta; 2011 Dec; 1811(12):1045-53. PubMed ID: 21983273
[TBL] [Abstract][Full Text] [Related]
15. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease.
Alkhouri N; Lopez R; Berk M; Feldstein AE
J Clin Gastroenterol; 2009; 43(10):985-9. PubMed ID: 19525859
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance in nonalcoholic fatty liver disease.
Bugianesi E; Moscatiello S; Ciaravella MF; Marchesini G
Curr Pharm Des; 2010 Jun; 16(17):1941-51. PubMed ID: 20370677
[TBL] [Abstract][Full Text] [Related]
17. Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis?
Cengiz C; Ardicoglu Y; Bulut S; Boyacioglu S
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):813-9. PubMed ID: 19820404
[TBL] [Abstract][Full Text] [Related]
18. [Adipocytokines and nonalcoholic steatohepatitis].
Lăcătuşu C; Mihai B; Mihai C; Cijevschi-Prelipcean C; Graur M
Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):345-52. PubMed ID: 21495339
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
Schäffler A; Schölmerich J; Büchler C
Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
[TBL] [Abstract][Full Text] [Related]
20. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
